Avantor Inc’s stock climbed to a 52‑week high of $15.94 on September 17, 2026, following a period of steady gains that included a 100 % return over the prior six months and a 23.64 % increase over the past year. The move was underpinned by the company’s second‑quarter results, which showed adjusted earnings of $0.21 per share, topping the consensus estimate of $0.19, and revenue of $1.69 billion, above the forecast of $1.61 billion.
The earnings beat was credited to stronger performance in the VWR distribution business and improved order trends in bioscience and medtech, as well as progress on Avantor’s Revival programs. In response, Jefferies raised its price target for the stock to $13.00 from $7.00 and upgraded its rating to Hold from Underperform, while Wolfe Research moved the rating to Peerperform. Data from InvestingPro indicated that eight analysts had recently revised their earnings expectations upward for the company.
InvestingPro also noted that, at current levels, the stock may be slightly overvalued, though it highlighted the availability of more than 1,400 Pro Research Reports, including a comprehensive analysis of Avantor. The combination of better‑than‑expected quarterly figures and analyst optimism pushed the shares to their yearly peak.
